Effects of atriopeptin III on isolated rat afferent and efferent arterioles
D. M. Lanese, B. H. Yuan, S. A. Falk and J. D. Conger Department of Medicine, University of Colorado Health Sciences Center, Denver. The effects of atriopeptin III (AP III) on in vitro prepared afferent (AA) and efferent arterioles (EA) from rat kidneys were tested in a system in which lumen diamete...
Gespeichert in:
| Veröffentlicht in: | American journal of physiology. Renal physiology 1991-12, Vol.261 (6), p.1102-F1109 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | F1109 |
|---|---|
| container_issue | 6 |
| container_start_page | 1102 |
| container_title | American journal of physiology. Renal physiology |
| container_volume | 261 |
| creator | Lanese, D. M Yuan, B. H Falk, S. A Conger, J. D |
| description | D. M. Lanese, B. H. Yuan, S. A. Falk and J. D. Conger
Department of Medicine, University of Colorado Health Sciences Center, Denver.
The effects of atriopeptin III (AP III) on in vitro prepared afferent (AA)
and efferent arterioles (EA) from rat kidneys were tested in a system in
which lumen diameter could be measured. AP III (10(-13)-10(-7) M) had no
effect on lumen diameter of AA that were not preconstricted. When AA were
preconstricted with either angiotensin II (ANG II) or norepinephrine (NE),
however, AP III increased lumen diameter in a concentration-dependent
manner to the preconstriction baseline value. Maximal vasodilation occurred
at 10(-10) M AP III. Unlike AA, EA constricted by 50% to 10(-10) M AP III
further constricted EA that were pretreated with ANG II or NE. Dilation in
ANG II-preconstricted AA to AP III was not inhibited by indomethacin.
Constriction of EA to AP III was not altered by [Sar1-Ala8] ANG II,
enalapril, OKY 046, or phentolamine. Results indicate that in isolated
renal arterioles AP III dilates preconstricted AA but constricts EA that
have either not been pretreated or have been preconstricted with other
agonists. The effect of AP III on preconstricted AA does not require
vasodilator prostaglandin mediation. The constrictor effect of AP III on EA
is not dependent on angiotensin, thromboxane, or alpha-adrenergic
mediation. |
| doi_str_mv | 10.1152/ajprenal.1991.261.6.F1102 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_highw</sourceid><recordid>TN_cdi_highwire_physiology_ajprenal_261_6_F1102</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72578967</sourcerecordid><originalsourceid>FETCH-LOGICAL-c284t-1d8494b5a204f5d0e6c44056a1eb848cab7ffd66af4d67e6aa8b3ca128caed913</originalsourceid><addsrcrecordid>eNpNkE1Pg0AQhjdGU2v1J5jgxRt0Z4EBjqZptbGJFz1vFphtaSjgLo3pv3cr1XqambwfkzyMPQAPAGIxVdvOUKPqALIMAoEQYLAA4OKCjQUg-M6VXLIxDzH0EURyzW6s3XIuBKY4YiNABJ6KMXuda01Fb71We6o3VdtR11eNt1wuvbbxKtvWqqfSM6r3lLO6t25pSo_-DtOTy9Vkb9mVVrWlu9OcsI_F_H324q_enpezp5VfiDTqfSjTKIvyWAke6bjkhEUU8RgVUJ5GaaHyROsSUemoxIRQqTQPCwXCSVRmEE7Y49DbmfZzT7aXu8oWVNeqoXZvZSLiJM0wccZsMBamtdaQlp2pdsocJHB5BCl_QcojSOlASpQ_IF32_vRkn--oPCcHck6fDvqmWm--KkOy2xys49CuD-fa_43fw1iDUw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72578967</pqid></control><display><type>article</type><title>Effects of atriopeptin III on isolated rat afferent and efferent arterioles</title><source>MEDLINE</source><source>Alma/SFX Local Collection</source><creator>Lanese, D. M ; Yuan, B. H ; Falk, S. A ; Conger, J. D</creator><creatorcontrib>Lanese, D. M ; Yuan, B. H ; Falk, S. A ; Conger, J. D</creatorcontrib><description>D. M. Lanese, B. H. Yuan, S. A. Falk and J. D. Conger
Department of Medicine, University of Colorado Health Sciences Center, Denver.
The effects of atriopeptin III (AP III) on in vitro prepared afferent (AA)
and efferent arterioles (EA) from rat kidneys were tested in a system in
which lumen diameter could be measured. AP III (10(-13)-10(-7) M) had no
effect on lumen diameter of AA that were not preconstricted. When AA were
preconstricted with either angiotensin II (ANG II) or norepinephrine (NE),
however, AP III increased lumen diameter in a concentration-dependent
manner to the preconstriction baseline value. Maximal vasodilation occurred
at 10(-10) M AP III. Unlike AA, EA constricted by 50% to 10(-10) M AP III
further constricted EA that were pretreated with ANG II or NE. Dilation in
ANG II-preconstricted AA to AP III was not inhibited by indomethacin.
Constriction of EA to AP III was not altered by [Sar1-Ala8] ANG II,
enalapril, OKY 046, or phentolamine. Results indicate that in isolated
renal arterioles AP III dilates preconstricted AA but constricts EA that
have either not been pretreated or have been preconstricted with other
agonists. The effect of AP III on preconstricted AA does not require
vasodilator prostaglandin mediation. The constrictor effect of AP III on EA
is not dependent on angiotensin, thromboxane, or alpha-adrenergic
mediation.</description><identifier>ISSN: 0363-6127</identifier><identifier>ISSN: 0002-9513</identifier><identifier>ISSN: 1931-857X</identifier><identifier>EISSN: 2161-1157</identifier><identifier>EISSN: 1522-1466</identifier><identifier>DOI: 10.1152/ajprenal.1991.261.6.F1102</identifier><identifier>PMID: 1661082</identifier><language>eng</language><publisher>United States</publisher><subject>Angiotensin II - pharmacology ; Animals ; Arterioles - drug effects ; Arterioles - physiology ; Atrial Natriuretic Factor - administration & dosage ; Atrial Natriuretic Factor - pharmacology ; Cyclooxygenase Inhibitors - pharmacology ; Dose-Response Relationship, Drug ; Kidney - blood supply ; Norepinephrine - pharmacology ; Peptide Fragments ; Phentolamine - pharmacology ; Rats ; Rats, Inbred Strains ; Receptors, Adrenergic, alpha - physiology ; Saralasin - pharmacology ; Thromboxane-A Synthase - antagonists & inhibitors ; Vasoconstriction - drug effects ; Vasodilation - drug effects</subject><ispartof>American journal of physiology. Renal physiology, 1991-12, Vol.261 (6), p.1102-F1109</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c284t-1d8494b5a204f5d0e6c44056a1eb848cab7ffd66af4d67e6aa8b3ca128caed913</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27903,27904</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1661082$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lanese, D. M</creatorcontrib><creatorcontrib>Yuan, B. H</creatorcontrib><creatorcontrib>Falk, S. A</creatorcontrib><creatorcontrib>Conger, J. D</creatorcontrib><title>Effects of atriopeptin III on isolated rat afferent and efferent arterioles</title><title>American journal of physiology. Renal physiology</title><addtitle>Am J Physiol</addtitle><description>D. M. Lanese, B. H. Yuan, S. A. Falk and J. D. Conger
Department of Medicine, University of Colorado Health Sciences Center, Denver.
The effects of atriopeptin III (AP III) on in vitro prepared afferent (AA)
and efferent arterioles (EA) from rat kidneys were tested in a system in
which lumen diameter could be measured. AP III (10(-13)-10(-7) M) had no
effect on lumen diameter of AA that were not preconstricted. When AA were
preconstricted with either angiotensin II (ANG II) or norepinephrine (NE),
however, AP III increased lumen diameter in a concentration-dependent
manner to the preconstriction baseline value. Maximal vasodilation occurred
at 10(-10) M AP III. Unlike AA, EA constricted by 50% to 10(-10) M AP III
further constricted EA that were pretreated with ANG II or NE. Dilation in
ANG II-preconstricted AA to AP III was not inhibited by indomethacin.
Constriction of EA to AP III was not altered by [Sar1-Ala8] ANG II,
enalapril, OKY 046, or phentolamine. Results indicate that in isolated
renal arterioles AP III dilates preconstricted AA but constricts EA that
have either not been pretreated or have been preconstricted with other
agonists. The effect of AP III on preconstricted AA does not require
vasodilator prostaglandin mediation. The constrictor effect of AP III on EA
is not dependent on angiotensin, thromboxane, or alpha-adrenergic
mediation.</description><subject>Angiotensin II - pharmacology</subject><subject>Animals</subject><subject>Arterioles - drug effects</subject><subject>Arterioles - physiology</subject><subject>Atrial Natriuretic Factor - administration & dosage</subject><subject>Atrial Natriuretic Factor - pharmacology</subject><subject>Cyclooxygenase Inhibitors - pharmacology</subject><subject>Dose-Response Relationship, Drug</subject><subject>Kidney - blood supply</subject><subject>Norepinephrine - pharmacology</subject><subject>Peptide Fragments</subject><subject>Phentolamine - pharmacology</subject><subject>Rats</subject><subject>Rats, Inbred Strains</subject><subject>Receptors, Adrenergic, alpha - physiology</subject><subject>Saralasin - pharmacology</subject><subject>Thromboxane-A Synthase - antagonists & inhibitors</subject><subject>Vasoconstriction - drug effects</subject><subject>Vasodilation - drug effects</subject><issn>0363-6127</issn><issn>0002-9513</issn><issn>1931-857X</issn><issn>2161-1157</issn><issn>1522-1466</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1991</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpNkE1Pg0AQhjdGU2v1J5jgxRt0Z4EBjqZptbGJFz1vFphtaSjgLo3pv3cr1XqambwfkzyMPQAPAGIxVdvOUKPqALIMAoEQYLAA4OKCjQUg-M6VXLIxDzH0EURyzW6s3XIuBKY4YiNABJ6KMXuda01Fb71We6o3VdtR11eNt1wuvbbxKtvWqqfSM6r3lLO6t25pSo_-DtOTy9Vkb9mVVrWlu9OcsI_F_H324q_enpezp5VfiDTqfSjTKIvyWAke6bjkhEUU8RgVUJ5GaaHyROsSUemoxIRQqTQPCwXCSVRmEE7Y49DbmfZzT7aXu8oWVNeqoXZvZSLiJM0wccZsMBamtdaQlp2pdsocJHB5BCl_QcojSOlASpQ_IF32_vRkn--oPCcHck6fDvqmWm--KkOy2xys49CuD-fa_43fw1iDUw</recordid><startdate>19911201</startdate><enddate>19911201</enddate><creator>Lanese, D. M</creator><creator>Yuan, B. H</creator><creator>Falk, S. A</creator><creator>Conger, J. D</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19911201</creationdate><title>Effects of atriopeptin III on isolated rat afferent and efferent arterioles</title><author>Lanese, D. M ; Yuan, B. H ; Falk, S. A ; Conger, J. D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c284t-1d8494b5a204f5d0e6c44056a1eb848cab7ffd66af4d67e6aa8b3ca128caed913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1991</creationdate><topic>Angiotensin II - pharmacology</topic><topic>Animals</topic><topic>Arterioles - drug effects</topic><topic>Arterioles - physiology</topic><topic>Atrial Natriuretic Factor - administration & dosage</topic><topic>Atrial Natriuretic Factor - pharmacology</topic><topic>Cyclooxygenase Inhibitors - pharmacology</topic><topic>Dose-Response Relationship, Drug</topic><topic>Kidney - blood supply</topic><topic>Norepinephrine - pharmacology</topic><topic>Peptide Fragments</topic><topic>Phentolamine - pharmacology</topic><topic>Rats</topic><topic>Rats, Inbred Strains</topic><topic>Receptors, Adrenergic, alpha - physiology</topic><topic>Saralasin - pharmacology</topic><topic>Thromboxane-A Synthase - antagonists & inhibitors</topic><topic>Vasoconstriction - drug effects</topic><topic>Vasodilation - drug effects</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lanese, D. M</creatorcontrib><creatorcontrib>Yuan, B. H</creatorcontrib><creatorcontrib>Falk, S. A</creatorcontrib><creatorcontrib>Conger, J. D</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of physiology. Renal physiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lanese, D. M</au><au>Yuan, B. H</au><au>Falk, S. A</au><au>Conger, J. D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effects of atriopeptin III on isolated rat afferent and efferent arterioles</atitle><jtitle>American journal of physiology. Renal physiology</jtitle><addtitle>Am J Physiol</addtitle><date>1991-12-01</date><risdate>1991</risdate><volume>261</volume><issue>6</issue><spage>1102</spage><epage>F1109</epage><pages>1102-F1109</pages><issn>0363-6127</issn><issn>0002-9513</issn><issn>1931-857X</issn><eissn>2161-1157</eissn><eissn>1522-1466</eissn><abstract>D. M. Lanese, B. H. Yuan, S. A. Falk and J. D. Conger
Department of Medicine, University of Colorado Health Sciences Center, Denver.
The effects of atriopeptin III (AP III) on in vitro prepared afferent (AA)
and efferent arterioles (EA) from rat kidneys were tested in a system in
which lumen diameter could be measured. AP III (10(-13)-10(-7) M) had no
effect on lumen diameter of AA that were not preconstricted. When AA were
preconstricted with either angiotensin II (ANG II) or norepinephrine (NE),
however, AP III increased lumen diameter in a concentration-dependent
manner to the preconstriction baseline value. Maximal vasodilation occurred
at 10(-10) M AP III. Unlike AA, EA constricted by 50% to 10(-10) M AP III
further constricted EA that were pretreated with ANG II or NE. Dilation in
ANG II-preconstricted AA to AP III was not inhibited by indomethacin.
Constriction of EA to AP III was not altered by [Sar1-Ala8] ANG II,
enalapril, OKY 046, or phentolamine. Results indicate that in isolated
renal arterioles AP III dilates preconstricted AA but constricts EA that
have either not been pretreated or have been preconstricted with other
agonists. The effect of AP III on preconstricted AA does not require
vasodilator prostaglandin mediation. The constrictor effect of AP III on EA
is not dependent on angiotensin, thromboxane, or alpha-adrenergic
mediation.</abstract><cop>United States</cop><pmid>1661082</pmid><doi>10.1152/ajprenal.1991.261.6.F1102</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0363-6127 |
| ispartof | American journal of physiology. Renal physiology, 1991-12, Vol.261 (6), p.1102-F1109 |
| issn | 0363-6127 0002-9513 1931-857X 2161-1157 1522-1466 |
| language | eng |
| recordid | cdi_highwire_physiology_ajprenal_261_6_F1102 |
| source | MEDLINE; Alma/SFX Local Collection |
| subjects | Angiotensin II - pharmacology Animals Arterioles - drug effects Arterioles - physiology Atrial Natriuretic Factor - administration & dosage Atrial Natriuretic Factor - pharmacology Cyclooxygenase Inhibitors - pharmacology Dose-Response Relationship, Drug Kidney - blood supply Norepinephrine - pharmacology Peptide Fragments Phentolamine - pharmacology Rats Rats, Inbred Strains Receptors, Adrenergic, alpha - physiology Saralasin - pharmacology Thromboxane-A Synthase - antagonists & inhibitors Vasoconstriction - drug effects Vasodilation - drug effects |
| title | Effects of atriopeptin III on isolated rat afferent and efferent arterioles |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-21T12%3A02%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_highw&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effects%20of%20atriopeptin%20III%20on%20isolated%20rat%20afferent%20and%20efferent%20arterioles&rft.jtitle=American%20journal%20of%20physiology.%20Renal%20physiology&rft.au=Lanese,%20D.%20M&rft.date=1991-12-01&rft.volume=261&rft.issue=6&rft.spage=1102&rft.epage=F1109&rft.pages=1102-F1109&rft.issn=0363-6127&rft.eissn=2161-1157&rft_id=info:doi/10.1152/ajprenal.1991.261.6.F1102&rft_dat=%3Cproquest_highw%3E72578967%3C/proquest_highw%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=72578967&rft_id=info:pmid/1661082&rfr_iscdi=true |